APPLICATION
ANDA207594
TYPE
ANDA
ORIGINAL APPROVAL
2019-12-12
LATEST ACTION
2024-04-04
ROUTE
INTRAVENOUS
DOSAGE FORM
POWDER
MARKETING STATUS
Prescription
Products
IMIPENEM AND CILASTATINPrescription
CILASTATIN SODIUM EQ 500MG BASE/VIAL, IMIPENEM 500MG/VIAL · POWDER · INTRAVENOUS
Approval history
2024-04-04Labeling · Supplement 2 · standardAP
2019-12-12UNKNOWN · Original · standardAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.